Current Pharmaceutical Design
July 31, 2026
Prachi Tayal, Rina Das, M.U. Khan et al.
BACKGROUND: Major depressive disorder (MDD) is one of the leading causes of disability globally, and conventional monoaminergic antidepressants often have a slow onset and limited efficacy. About onethird of patients suffer from treatment-resistant depression (TRD), which emphasizes the urgent need for alternative therapies. This review aims to systematically evaluate the available data about...
Current Pharmaceutical Design
February 28, 2025
Mei Ding, Ping Pei, Weihua Liu et al.
3 citations
As a heterogeneous clinical syndrome, acute respiratory distress syndrome (ARDS) is caused by infection-associated inflammation with limited treatment options. Esketamine possesses antiinflammatory properties, and it is effective in treating lung diseases. This study aimed to unveil the efficacy and mechanism of esketamine in ARDS. Lipopolysaccharide (LPS) is widely used to induce inflammatory...
Current Pharmaceutical Design
October 19, 2018
Jeffrey M. Witkin, Daniel E. Knutson, Gabriel J. Rodriguez et al.
44 citations
Background: Conventional antidepressants are thought to produce their impact on clinical symptoms by increasing the central availability of biogenic amine neurotransmitters (the monoamine hypothesis of depression). These drugs continue to be the primary medicines used in major depressive disorder. Although they have biological effects after acute dosing, full antidepressant response generally...
Current Pharmaceutical Design
January 30, 2018
Camille Richeval, Delphine Allorge, Xavier Vanhoye et al.
6 citations
Lysergic acid diethylamide (LSD) is a powerful hallucinogen, active at very low dosages, with, as a direct consequence, potential difficulties to be detected and quantified in a clinical or forensic context, in body fluids and even more in hair. The aim of this work is to review literature data related to hair analysis of LSD with a particular focus on the main issues encountered in LSD...
Current Pharmaceutical Design
May 10, 2014
Johannes Wrege, André Schmidt, Anna Walter et al.
96 citations
We conducted a systematic review to assess the evidence for specific effects of cannabis on impulsivity, disinhibition and motor control. The review had a specific focus on neuroimaging findings associated with acute and chronic use of the drug and covers literature published up until May 2012. Seventeen studies were identified, of which 13 met the inclusion criteria; three studies investigated...
Current Pharmaceutical Design
September 12, 2012
Rocío Martín‐Santos, José Alexandre S. Crippa, Albert Batalla et al.
288 citations
RATIONALE: Animal and humans studies suggest that the two main constituents of cannabis sativa, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have quite different acute effects. However, to date the two compounds have largely been studied separately. OBJECTIVE: To evaluate and compare the acute pharmacological effects of both THC and CBD in the same human volunteers. METHODS: A...
Current Pharmaceutical Design
2012
Niklaus Denier, Marc Walter, Kerstin Bendfeldt et al.
We conducted a systematic review on resting state cerebral blood flow activities found in first-episode psychosis (FEP) and during acute effects of cannabinoids and opioids, mental states that can be profoundly different from normal functioning. The main goal was to identify connections of cerebral blood flow measure and regional brain activity patterns associated with subjective experiences...
Current Pharmaceutical Design
2002
Chihiro Ito
Although the etiology of drug psychosis or schizophrenia is still unknown, molecular and biochemical researches have recently made significant advances in the search for the candidate genes of these disorders. Among such studies are animal models of drug psychosis or schizophrenia such as amphetamine-induced behavioral sensitization or phencyclidine-treated animals. In this review, it is...